Journal: British Journal of Cancer

Article Title: A human cancer-associated truncation of MBD4 causes dominant negative impairment of DNA repair in colon cancer cells

doi: 10.1038/sj.bjc.6603592

Figure Lengend Snippet: Dominant negative inhibition of glycosylase activities in cell-free glycosylase assays. ( A ) Oligo substrate BH:BHrev containing T.G mismatch, and FL-MBD4 competed with MBD4 tru . ( B ) Oligo substrate MM2:MM3revU containing U.G mismatch, and FL-MBD4 competed with MBD4 tru . ( C ) Oligo substrate BH:BHrevU containing U.G mismatch, and UDG competed with MBD4 tru . In each case, ‘+’ indicates presence and ‘−’ absence of protein, and the wedge indicates relative concentration of MBD4 tru in roughly two-fold increments from 1 to 10 ( A ) or from 1 to 20 ( B , C ). Vertical lines indicate where lanes have been juxtaposed owing to removal of an intervening, non-two-fold incremental lane.

Article Snippet: The role of MBD4 as a methyl-CpG-focused DNA mismatch glycosylase was subsequently supported by increases in mutation frequency at CpG sites in mouse models lacking Mbd4 ( Millar et al , 2002 ; Wong et al , 2002 ).

Techniques: Dominant Negative Mutation, Inhibition, Concentration Assay

Journal: Annals of Translational Medicine

Article Title: Circulating tumour DNA analysis for early detection of lung cancer: a systematic review

doi: 10.21037/atm-23-1572

Figure Lengend Snippet: Studies on the use of ctDNA analysis for early detection of lung cancer

Article Snippet: 36175411 , Stackpole et al. , 2022 ( ) , Pan-cancer , cfDNA methylation markers , 23,748 cancer-specific hypermethylation markers, 28,197 cancer-specific hypomethylation markers, 7,547 tissue-specific hypermethylation markers, 7,212 tissue-specific hypomethylation markers , Lung cancer (N=126), other cancers (N=150); stage I/II/III/IV =33/23/30/40, histological subtype (LUAD/LUSC) =77/49 , Non-cancer (healthy individuals and patients of various noncancer diseases (e.g., cirrhosis, pancreatitis, hepatitis, diabetes, etc.), N=203) , Integrating four marker types (all cancer types (n=217) vs. noncancer (n=191): sen./spec.=80.7%/97.9%, AUC =0.974.

Techniques: Biomarker Discovery, Concentration Assay, Amplification, Mutagenesis, Control, Clinical Proteomics, Methylation, DNA Methylation Assay, Computed Tomography, In Situ, Marker, Comparison, Diagnostic Assay, Genome Wide, RNA Expression